Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases

• DOI: 10.1111/bjh.20052
• Publication Date: 2025-03-20T06:27:26Z
• Authors: Sean McKeague; Molly Robertson; Sam van der Linde; Christine Khoo; Jonathan Segal; Sean Harrop; Adrian Minson; Andrew W. Roberts; Michael Dickinson

SummaryGlofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated faecal calprotectin, abnormal bowel avidity on positron emission tomography scan (2/3), absence of CD20‐positive B cells on gut histology and steroid responsiveness. There was variability in the area of gastrointestinal inflammation, severity of symptoms, histological findings and impact on subsequent therapy. The mechanism for this phenomenon is unknown. Possible explanations include B‐regulatory cell depletion and T‐cell recruitment to the gastrointestinal tract because of CD20 antigen density. Clinicians should consider this toxicity in glofitamab‐treated patients presenting with sustained diarrhoea or abdominal pain when infectious colitis has been comprehensively excluded.